ZA201606519B - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen

Info

Publication number
ZA201606519B
ZA201606519B ZA2016/06519A ZA201606519A ZA201606519B ZA 201606519 B ZA201606519 B ZA 201606519B ZA 2016/06519 A ZA2016/06519 A ZA 2016/06519A ZA 201606519 A ZA201606519 A ZA 201606519A ZA 201606519 B ZA201606519 B ZA 201606519B
Authority
ZA
South Africa
Prior art keywords
modulator
immediate release
dosage regimen
release dosage
regimen
Prior art date
Application number
ZA2016/06519A
Other languages
English (en)
Inventor
Frank Dahlke
Emeric Reynaud
Erik Wallstroem
Eric Legangneux
Philippe Michael Rene Bouillot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201606519(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201606519B publication Critical patent/ZA201606519B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2016/06519A 2014-04-10 2016-09-21 S1p modulator immediate release dosage regimen ZA201606519B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
ZA201606519B true ZA201606519B (en) 2017-11-29

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/06519A ZA201606519B (en) 2014-04-10 2016-09-21 S1p modulator immediate release dosage regimen

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP4074312A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN116650467A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US20200316021A1 (en) * 2017-09-29 2020-10-08 Novartis Ag Dosing Regimen of Siponimod
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案
HRP20250115T1 (hr) * 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171785A1 (en) * 2008-12-18 2011-07-28 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
DK2379067T3 (en) * 2008-12-22 2015-12-07 Novartis Ag Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
CA2773330C (en) * 2009-09-29 2021-11-02 Novartis Ag Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
KR20140084041A (ko) * 2011-10-21 2014-07-04 노파르티스 아게 S1p 수용체 조절제 또는 효능제에 대한 투여 요법
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Also Published As

Publication number Publication date
EP4074312A1 (en) 2022-10-19
CA2943598C (en) 2023-03-07
US20220016076A1 (en) 2022-01-20
SG11201607894RA (en) 2016-10-28
JP6674903B2 (ja) 2020-04-01
MX2016013245A (es) 2017-01-16
RU2016143979A (ru) 2018-05-14
US20190054065A1 (en) 2019-02-21
US20250041266A1 (en) 2025-02-06
JP2017510607A (ja) 2017-04-13
CL2016002562A1 (es) 2017-07-28
RU2715734C2 (ru) 2020-03-03
RU2016143979A3 (enExample) 2018-11-12
EP3831378A1 (en) 2021-06-09
AU2020203107B2 (en) 2021-10-21
IL247986A0 (en) 2016-11-30
CA2943598A1 (en) 2015-10-15
AU2015246036A1 (en) 2016-10-13
CN106456552A (zh) 2017-02-22
KR20160141841A (ko) 2016-12-09
CN116650467A (zh) 2023-08-29
PH12016501965A1 (en) 2017-01-09
EP3129020A1 (en) 2017-02-15
KR20220156981A (ko) 2022-11-28
US20170027907A1 (en) 2017-02-02
AU2020203107A1 (en) 2020-05-28
IL305337A (en) 2023-10-01
TW201622721A (zh) 2016-07-01
RU2020107732A (ru) 2020-03-30
WO2015155709A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
IL247986A0 (en) A therapeutic regimen containing an immediate release dose of an s1p modulator
GB201404922D0 (en) Pharmaceutical compounds
PT3145836T (pt) Cápsula de dispensação
SI3022458T1 (sl) Povezava zavornega diska in pesta
PL3363428T3 (pl) Perfuzyjna postać dawkowania
GB201412955D0 (en) Supramolecular capsules
IL247083A0 (en) dose fgh–18
GB201416513D0 (en) Pharmaceutical compounds
GB201417707D0 (en) Pharmaceutical compounds
SI3145497T1 (sl) Obložene kapsule s prirejenim sproščanjem
SI3145499T1 (sl) Obložene kapsule s prirejenim sproščanjem
EP3011948A4 (en) DEVICE FOR DISPENSING RADIOPHARMACEUTICAL PRODUCTS
GB201418710D0 (en) Dosage regimen
GB2531773B (en) Medicine pack
SI3139932T1 (sl) Režim zdravljenja za spojino tiacumicina
HK1227759A1 (en) S1p modulator immediate release dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201508022D0 (en) Pharmaceutical compounds
AU362816S (en) Capsule
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds